Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Oncology Institute (TOI) Invested Capital (2020 - 2025)

Historic Invested Capital for Oncology Institute (TOI) over the last 6 years, with Q3 2025 value amounting to $63.9 million.

  • Oncology Institute's Invested Capital fell 4027.14% to $63.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $63.9 million, marking a year-over-year decrease of 4027.14%. This contributed to the annual value of $96.7 million for FY2024, which is 3276.38% down from last year.
  • Latest data reveals that Oncology Institute reported Invested Capital of $63.9 million as of Q3 2025, which was down 4027.14% from $66.0 million recorded in Q2 2025.
  • Oncology Institute's Invested Capital's 5-year high stood at $207.0 million during Q3 2022, with a 5-year trough of $47.1 million in Q1 2021.
  • Over the past 5 years, Oncology Institute's median Invested Capital value was $119.2 million (recorded in 2024), while the average stood at $117.2 million.
  • In the last 5 years, Oncology Institute's Invested Capital soared by 38621.83% in 2021 and then tumbled by 4457.85% in 2025.
  • Quarter analysis of 5 years shows Oncology Institute's Invested Capital stood at $104.2 million in 2021, then skyrocketed by 95.66% to $203.8 million in 2022, then decreased by 29.41% to $143.9 million in 2023, then plummeted by 32.76% to $96.7 million in 2024, then crashed by 33.91% to $63.9 million in 2025.
  • Its last three reported values are $63.9 million in Q3 2025, $66.0 million for Q2 2025, and $79.0 million during Q1 2025.